Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01191723 · ClinicalTrials.gov registry record · Phase 1

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

A Phase 1 study of Healthy, sponsored by Allergan.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target
1
Study location

NCT01191723 is a Phase 1 study of Healthy that has completed, run by Allergan. The registered enrollment target is 54 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01191723, a Phase 1 study of Healthy, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Compare the acute effect on the QT interval of MAP0004 (Dihydroergotamine Mesylate delivered by Oral Inhalation) with Moxifloxacin and Placebo.

Conditions Studied

Healthy

Interventions

  • DRUG Moxifloxacin
  • DRUG Placebo Capsule
  • DRUG MAP0004
  • DRUG Inhaler Placebo

Study Locations (1)

North Dakota

  • Cetero Research - Fargo

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2010-08
Est. Completion 2010-09
Phase Phase 1

Sponsor

Allergan

314 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01191723

The ClinicalTrials.gov registry entry for NCT01191723 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Moxifloxacin is the first listed.

NCT01191723 reports 1 study location spanning 1 distinct geographic area - top geographies include North Dakota.

Frequently Asked Questions

What is clinical trial NCT01191723 about?

NCT01191723 is a clinical study titled "QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo". Compare the acute effect on the QT interval of MAP0004 (Dihydroergotamine Mesylate delivered by Oral Inhalation) with Moxifloxacin and Placebo.

What is the current status of trial NCT01191723?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2010-08. Estimated completion is 2010-09.

What conditions does trial NCT01191723 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT01191723?

The interventions under investigation include: Moxifloxacin (DRUG), Placebo Capsule (DRUG), MAP0004 (DRUG), Inhaler Placebo (DRUG).

Who is sponsoring clinical trial NCT01191723?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01191723 being conducted?

This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

North Dakota

All trials with a study site in North Dakota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.